文献速递急性肾损伤慢性肾脏病

近端小管来源双调蛋白放大并整合促纤维化EGFR信号

Proximal Tubule-Derived Amphiregulin Amplifies and Integrates Profibrotic EGF Receptor Signals in Kidney Fibrosis.
PubMed 文献 · J Am Soc Nephrol · 2019-11-01

本研究探讨近端小管细胞中EGFR持续激活的分子机制及配体。体外实验显示YAP1依赖的双调蛋白上调通过正反馈放大信号,并整合其他低亲和力EGFR配体。小鼠缺血再灌注或单侧输尿管梗阻模型中,近端小管特异性敲除双调蛋白可减轻纤维化,而注射可溶性双调蛋白可逆转保护效应。

要点

  • 双调蛋白是损伤诱导肾纤维化的关键分子。
  • YAP1依赖的双调蛋白正反馈放大EGFR信号。
  • 可溶性双调蛋白注射可逆转小鼠纤维化保护。

核心结论

  • 双调蛋白是损伤诱导肾纤维化的关键驱动因子,可溶性双调蛋白具有治疗或诊断应用潜力。

研究设计与样本

  • 体外研究近端小管细胞及损伤肾脏原代小管细胞的EGFR激活。
  • 体内使用近端小管细胞特异性双调蛋白敲除小鼠,行缺血再灌注损伤或单侧输尿管梗阻。
  • 向近端小管细胞特异性ADAM17敲除小鼠及ADAM17低功能小鼠注射可溶性双调蛋白。

主要发现

  • YAP1依赖的双调蛋白转录和蛋白上调通过正反馈环路放大双调蛋白信号。
  • YAP1整合其他损伤上调的低亲和力EGFR配体(epiregulin、epigen、TGFα)信号,这些配体也需可溶性双调蛋白和YAP1才能诱导体外近端小管细胞持续EGFR激活。
  • 体内注射可溶性双调蛋白足以逆转ADAM17低功能小鼠缺血再灌注损伤后的纤维化保护。
  • 注射可溶性双调蛋白也逆转近端小管细胞特异性ADAM17敲除小鼠损伤后的保护表型。
  • 近端小管细胞特异性双调蛋白敲除小鼠在缺血再灌注损伤或单侧输尿管梗阻后纤维化减轻。

临床怎么用

  • 可溶性双调蛋白可能作为肾纤维化的治疗靶点或诊断标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sustained activation of EGF receptor (EGFR) in proximal tubule cells is a hallmark of progressive kidney fibrosis after AKI and in CKD. However, the molecular mechanisms and particular EGFR ligands involved are unknown. METHODS: We studied EGFR activation in proximal tubule cells and primary tubular cells isolated from injured kidneys in vitro. To determine in vivo the role of amphiregulin, a low-affinity EGFR ligand that is highly upregulated with injury, we used ischemia-reperfusion injury or unilateral ureteral obstruction in mice with proximal tubule cell-specific knockout of amphiregulin. We also injected soluble amphiregulin into knockout mice with proximal tubule cell-specific deletion of amphiregulin's releasing enzyme, the transmembrane cell-surface metalloprotease, a disintegrin and metalloprotease-17 (ADAM17), and into ADAM17 hypomorphic mice. RESULTS: Yes-associated protein 1 (YAP1)-dependent upregulation of amphiregulin transcript and protein amplifies amphiregulin signaling in a positive feedback loop. YAP1 also integrates signals of other moderately injury-upregulated, low-affinity EGFR ligands (epiregulin, epigen, TGFα), which also require soluble amphiregulin and YAP1 to induce sustained EGFR activation in proximal tubule cells in vitro. In vivo, soluble amphiregulin injection sufficed to reverse protection from fibrosis after ischemia-reperfusion injury in ADAM17 hypomorphic mice; injected soluble amphiregulin also reversed the corresponding protective proximal tubule cell phenotype in injured proximal tubule cell-specific ADAM17 knockout mice. Moreover, the finding that proximal tubule cell-specific amphiregulin knockout mice were protected from fibrosis after ischemia-reperfusion injury or unilateral ureteral obstruction demonstrates that amphiregulin was necessary for the development of fibrosis. CONCLUSIONS: Our results identify amphiregulin as a key player in injury-induced kidney fibrosis and suggest therapeutic or diagnostic applications of soluble amphiregulin in kidney disease.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Kefaloyianni E, Keerthi Raja MR, Schumacher J, et al. Proximal Tubule-Derived Amphiregulin Amplifies and Integrates Profibrotic EGF Receptor Signals in Kidney Fibrosis. J Am Soc Nephrol. 2019. PMID: 31676723. doi:10.1681/ASN.2019030321

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。